Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au